51052-62-1 Usage
Description
Memantine hydrochloride is a potent N-methyl-D-aspartate (NMDA) receptor antagonist that was co-developed by Forest Laboratories with Merz Pharmaceuticals. It is marketed under the trade name Namenda and has been approved for the treatment of Alzheimer's disease in the US since October 2003. This medication is also available in various European and Asian markets.
Uses
Used in Pharmaceutical Industry:
Memantine hydrochloride is used as a therapeutic agent for the treatment of Alzheimer's disease. It functions by blocking excessive stimulation of NMDA receptors, which helps to prevent the neuronal damage caused by excitotoxicity and supports cognitive function in patients with Alzheimer's.
Used in Neuroprotection:
Memantine hydrochloride is used as a neuroprotective agent to safeguard neurons from excitotoxicity, which is a significant factor in the progression of neurodegenerative diseases like Alzheimer's. By modulating the activity of NMDA receptors, it helps to maintain a balance between neuronal excitation and inhibition, thus promoting overall brain health.
Used in Clinical Trials for Other Neurological Disorders:
Memantine hydrochloride is also being investigated for its potential use in treating other neurological disorders, such as Parkinson's disease, Huntington's disease, and multiple sclerosis. Its NMDA receptor antagonistic properties make it a promising candidate for managing the symptoms and progression of these conditions.
in vitro
Memantine（3，5-dimethyl-Tricyclo[3.3.1.13,7]decan-1-amine） is an NMDA receptor antagonist that blocks NMDA-induced currents in rat retinal ganglion cells by 90% when used at a concentration of 12 μM. It reverses inhibition of dephosphorylation of the synthetic tau phosphopeptide p17 (tau194-207) induced by the endogenous inhibitor of protein phosphatase 2A (PP2A) I1PP2A in vitro.
in vivo
In vivo, memantine (2 mg/kg) restores PP2A activity, decreases GSK-3β and amyloid-β (Aβ) levels in the hippocampus, cerebral cortex, and ventricular areas, and attenuates spatial learning and memory in the AAV1-I1PP2A rat model of Alzheimer''s disease. Memantine (20 mg/kg) reduces responding on the ethanol-associated lever in a cue-induced ethanol-seeking test in rats. It also decreases secretion of matrix metalloproteinase-9 (MMP-9), degradation of collagen IV, the size of cerebral ischemia-induced brain infarcts, and neuronal cell death in a mouse model of focal cerebral ischemia.
Check Digit Verification of cas no
The CAS Registry Mumber 51052-62-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,1,0,5 and 2 respectively; the second part has 2 digits, 6 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 51052-62:
(7*5)+(6*1)+(5*0)+(4*5)+(3*2)+(2*6)+(1*2)=81
81 % 10 = 1
So 51052-62-1 is a valid CAS Registry Number.
InChI:InChI=1/C8H14N2O2/c1-2-6(8(9)12)10-5-3-4-7(10)11/h6H,2-5H2,1H3,(H2,9,12)/t6-/m0/s1
51052-62-1Relevant articles and documents
Green preparation method of memantine
-
Paragraph 0047-0056, (2021/09/15)
The method comprises the following steps: (1) mixing 1 - chlorine -3 and 5 - dimethyl adamantane with acetamide to obtain 1 -acetylamino -3 and 5 -dimethyladamantane. (2) The 1 -acetylamino -3, 5 -dimethyladamantane was deacetylated in a hot-water system to obtain a memantine. The preparation method provided by the invention is simple to operate. The method is safe, environment-friendly, high in yield and purity, cost-saving, low in production cost and beneficial to industrial production.
Memantine hydrochloride synthesis method
-
Paragraph 0061; 0067-0070; 0074; 0080-0084' 0088; 0094-0098, (2020/03/09)
The invention provides a memantine hydrochloride synthesis method, and belongs to the technical field of medicine synthesis. The preparation method comprises the following steps: carrying out a substitution reaction on 1-bromo-3,5-dimethyladamantane and acetamide to obtain 1-acetamido-3,5-dimethyladamantane, mixing the 1-acetamido-3,5-dimethyladamantane, an alcohol and an alkali, carrying out an alcoholysis reaction to obtain 1-amino-3,5-dimethyladamantane, and finally carrying out an acidification reaction on the 1-amino-3,5-dimethyladamantane and hydrochloric acid to obtain memantine hydrochloride. According to the method of the invention, 1-bromo-3,5-dimethyl adamantane and acetamide are used as the starting raw materials, so the sources of the raw materials are wide, the use of acetonitrile is avoided, and no pollution is caused to the human body and the environment; the use of catalysts is avoided in the whole reaction process, the reaction product is easy to separate, and the yield of the obtained memantine hydrochloride is high; and the method is mild in reaction condition and suitable for industrial production.
Deacetylative Amination of Acetyl Arenes and Alkanes with C-C Bond Cleavage
Hyodo, Kengo,Hasegawa, Genna,Maki, Hiroya,Uchida, Kingo
supporting information, p. 2818 - 2822 (2019/04/25)
The Br?nsted acid-catalyzed synthesis of primary amines from acetyl arenes and alkanes with C-C bond cleavage is described. Although the conversion from an acetyl group to amine has traditionally required multiple steps, the method described herein, which uses an oxime reagent as an amino group source, achieves the transformation directly via domino transoximation/Beckmann rearrangement/Pinner reaction. The method was also applied to the synthesis of γ-aminobutyric acids, such as baclophen and rolipram.
